All treatments
Treatment
Epcoritamab (GEN3013) clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
This study is looking at a new medicine called epcoritamab for children and young people with a type of aggressive blood cancer that has come back or not responded to previous treatments. The main goal is to check if the medicine is safe and how well the body handles it.
For: Relapsed/Refractory Aggressive Mature B-cell NeoplasmsItaly · Germany · Czechia - AuthorisedPhase I and Phase II (Integrated)- Other
HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstrom’s macroglobulinemia
This study is testing a new medicine called epcoritamab for people with a type of blood cancer called Waldenstrom’s macroglobulinemia. It's for patients whose cancer has come back or hasn't responded to other treatments. The aim is to see if the medicine is safe and helps shrink the cancer.
For: relapsed or refractory Waldenstrom’s macroglobulinemiaDenmark · Belgium · Netherlands